Rat pituitary cells release ACTH
A thymic peptide reaches a different biological conversation. The measurement here is hormone release.
Cultured pituitary cells
Zinc-bound thymulin stimulated immunoreactive ACTH release from rat anterior pituitary cells in vitro. The maximal effect was near 10 pM, with parallel changes in cyclic nucleotide formation. That concentration describes the cell experiment, not a human dose.
I had expected thymulin's immune role to dominate the story. An ACTH measurement moves the question into a different set of cells. The review of the thymus–neuroendocrine axis describes the relationship in both directions: the neuroendocrine system influences thymulin production, and thymulin can act on the pituitary.
That is a satisfying connection to investigate. It is also narrower than an account of stress or resilience in a whole person. The original experiment measured a response in rat cells, and ACTH is enough to surprise me here; a claim about how a person feels would require a different experiment.
Immune-cell markers
The older human marrow-precursor study examined synthetic serum thymic factor in culture. It reported induction of T-cell surface markers, including T-cell phenotypes and E-rosette formation. This is human-cell evidence, with the cells studied outside the body.
Those marrow cells require a separate compartment in my thinking. Both help explain why thymulin appears in an immune–endocrine discussion. Neither supplies a general measure of a person's immune strength, and the experiments test different cell types and responses.
The zinc-interaction review adds another condition: thymulin's biological activity depends on bound zinc. Its chemistry deserves attention even when the destination of the signal changes.
Hormone development in athymic mice
Neonatal gene therapy in congenitally athymic female mice used the adenoviral vector RAd-metFTS. It prevented deficits in circulating LH and FSH and ovarian dysgenesis. These mice lacked a thymus; that starting condition is central to the developmental question.
The preparation also changes. Genetic instructions delivered by a vector make this a distinct intervention from adding zinc-bound thymulin to pituitary cells. The developmental reach of that question impresses me. The preparations remain distinct.
The junction suggested by Nexora has become quite specific: immune tissue, endocrine cells and development. Returning to the pain experiments means returning to different outcomes and different subjects.